Incidence of hibernating myocardium after acute myocardial infarction treated with thrombolysis

Heart

Volumn 75, Issue 5, 1996, Pages 442-446

  Adams, J N ^a,c   Norton, M ^b   Trent, R J ^a   Mikecz, P ^b   Walton, S ^a   Evans, N ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Hibernating myocardium; Myocardial infarction; Positron emission tomography

Indexed keywords

AMMONIA; FLUORODEOXYGLUCOSE F 18; NITROGEN 13; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIBERNATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX PAIN;

EID: 0029975415     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.75.5.442     Document Type: Article

References (28)

1. Rahimtoola SHG. A perspective on the three large multicenter randomized clinical trials of coronary artery bypass surgery for unstable angina. Circulation 1985;72(suppl V):V123.
2. Braunwald E, Rutherford JD. Reversible ischaemic left ventricular dysfunction; evidence for the "hibernating myocardium". J Am Coll Cardiol 1986;8:1467-70.
3. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, et al. Coronary thrombolysis with recombinant human tissue type plasminogen activator: a prospective randomized placebo-controlled trial. Circulation 1984;70: 1012-7.
4. Topol EJ, O'Neil WW, Langburd AB, Walton JA, Bourdillon BDV, Grines CL, et al. A randomised placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation 1987;75:420-8.
5. Schwaiger M, Brunken RC, Krivokapich J, Child S, Tillisch JH, Phelps ME. Beneficial effect of residual antegrade flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J 1987;8:981-8.
6. Takeishi Y, Tono-oka I, Kubota I Ikeda K, Masakane I, Chiba J, et al. Functional recovery of hibernating myocardium after coronary bypass surgery: Does it coincide with improvement in perfusion? Am Heart J 1991;122: 665-70.
7. Marwick TH, Nemec JJ, Lafont A, Salecedo E, MacIntyre WJ. Prediction by post exercise fluoro-18-deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 1992;69: 854-9.
8. Neinaber CA, Brunken RC, Marshall R, Sherman CT, Yeatman LA, Gambhir SS, et al. Metabolic and functional recovery of ischaemic human myocardium after coronary angioplasty. Am J Coll Cardiol 1991;18:966-78.
9. Eitzman D, Al-Aquar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;3:559-65.
10. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
11. 18F-labelled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766-78.
12. Lange K, Carson R. EM reconstruction algorithms for emission and transmission tomography. J Comput Assist Tomogr 1984;8:306-16.
13. Goris ML, Thomson C, Malone L, Franken PR. Modelling the integration of myocardial regional perfusion and function. Nucl Med Commun 1994;15:9.
14. Gould KL. Clinical cardiac positron emission tomography: state of the art. Circulation 1991;84(suppl I):I22-3.6.
15. Downing SE, Chen V. Acute hibernation and reperfusion of the ischaemic heart. Circulation 1992;82:699-707.
16. Schwaiger M, Brunken R, Grover-McKay M, Krivokapich J, Child J, Tillisch JH, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986;4:800-8.
17. Czernin J, Porenta G, Brunken R, Krivokapich J, Chen K, Bennett R, et al. Regional blood flow, oxidative metabolism and glucose utilization in patients with recent myocardial infarction. Circulation 1993;88:884-95.
18. Schoeder H, Friedrich M, Topp H. Myocardial viability: what do we need? Eur J Nucl Med 1993;20:792-803.
19. Pierard L, De Iandsheere C, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990;15:1021-31.
20. Scheibert HR, Phelps ME, Hoffman EJ, Huang SC, Selin CE, Kuhl DE. Regional myocardial perfusion assessed with N-13 labelled ammonia and positron emission computerised axial tomography. Am J Cardiol 1979;43:209.
21. Scheibert HR, Phelps ME, Huang SC, MacDonald NS, Hansen H, Selin C, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation 1981;63:1259-72.
22. 3 by myocardium on metabolic factors and its implications for the quantitative assessment of perfusion. Circulation 1978; 61:34-41.
23. Vanoverschelde JL, Melin JA, Bol A, Vanbutsele R, Cogneau M, Labar D, et al. Regional oxidative metabolism in patients after recovery from reperfused anterior myocardial infarction. Relation to regional blood flow and glucose uptake. Circulation 1992;85:9-21.
24. Lui P, Kiess MC, Okada RD. The persistent defect on exercise thallium imaging and its fate after myocardial revascularisation: does it represent scar or ischaemia? Am Heart J 1985;110:996-1001.
25. Dilsizian V, Rocco TP, Freedman NMT, Leon MB, Bonow RO. Enhanced detection of ischaemic but viable myocardium by the re-injection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-6.
26. Brunken R, Schwaiger M, Grover-McKay M, Phelps ME, Tillisch J, Scheibert HR. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol 1987;10:557-67.
27. Brunken RC, Kottou S, Nienaber CA, Schwaiger M, Ratib OM, Phelps ME, et al. PET detection of viable tissue in myocardial segments with persistent defects at T1-201 SPECT. Radiology 1989;172:65-73.
28. 18F-fluorodeoxyglucose. Circulation 1991;83:26-37.